Tff Pharmaceuticals, Inc. Stock News

Preclinical studies show that TFF Pharmaceuticals Inc''s (NASDAQ: TFFP ) inhaled niclosamide product candidate inhibits viral replication of both the Delta and Omicron variants of SARS-CoV-2 . More specifically, nirmatrelvir and molnupiravir showed complete inhibition of the Omicron variant at 2.5 μM. In the studies announced today by TFF Pharmaceuticals, inhaled niclosamide demonstrated complete inhibition of Omicron at … Full story available on Benzinga.com

TFF Pharmaceuticals <> said in vitro neutralization and viral replication assays suggested that its inhaled niclosamide product candidate completely inhibits viral replication of…

By StoryTrading Pfizer collaboration just revealed in presentation update - no PR issued yet!

Progenity: The Transition Is Well Under Way

After a long and painful downside, TFFP's stock has finally delivered a one-day outperformance with respect to the big Covid plays due to the Omicron variant. The next question is whether this is just

Zacks Investment Research downgraded shares of TFF Pharmaceuticals (NASDAQ:TFFP) from a hold rating to a sell rating in a research report report published on Friday, Zacks.com reports. According to Zacks, TFF Pharmaceuticals Inc. is an early-stage biopharmaceutical company. It is focused on the development and commercialization of inhalation products for the treatment of chronic respiratory []

Related Stocks: SWN , TFFP , VET , CVE , SRUUF , CCJ , MAXR , REPL , COIN , RETA , QS , CRDF ,

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q3 2021 Results - Earnings Call Transcript

Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs; Both Programs Advancing into Phase 2 Testing

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -142.86% and -97.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

Results published in bioRxiv Show That Delivery of Dry Powder AUG-3387 Following Viral Inoculation Led to Dose-Dependent Reduction in Lung Viral Load in Hamsters

TFF Pharmaceuticals Inc (NASDAQ: TFFP) has announced topline results from Phase 1 trial for Tacrolimus Inhalation Powder. Data showed a good safety profile and demonstrating that therapeutic drug l

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug produ